Matthias Weiss MD, Dr. med. - ThedaCare ...

Dr. Matthias Weiss

Claim this profile

ThedaCare Regional Cancer Center

Expert in Cancer
Expert in Lung Cancer
41 reported clinical trials
75 drugs studied

Area of expertise

1

Cancer

Global Leader

Matthias Weiss has run 11 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive
2

Lung Cancer

Global Leader

Matthias Weiss has run 11 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

ThedaCare Regional Cancer Center

Image of trial facility.

ThedaCare Regional Medical Center - Neenah

Clinical Trials Matthias Weiss is currently running

Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.

Recruiting

1 award

Phase 2

31 criteria

Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Recruiting

0 awards

Phase 2

32 criteria

More about Matthias Weiss

Clinical Trial Related

7 years of experience running clinical trials · Led 41 trials as a Principal Investigator · 13 Active Clinical Trials

Treatments Matthias Weiss has experience with

  • Carboplatin
  • Paclitaxel
  • Nivolumab
  • Biospecimen Collection
  • Pembrolizumab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Matthias Weiss specialize in?

Is Matthias Weiss currently recruiting for clinical trials?

Are there any treatments that Matthias Weiss has studied deeply?

What is the best way to schedule an appointment with Matthias Weiss?

What is the office address of Matthias Weiss?

Is there any support for travel costs?